Who are Placebo Lonafarnib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zokinvy, Tipifarnib;Zarnestra; R115777, Gemcitabine with R115777.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-lonafarnib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo Lonafarnib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo Lonafarnib (Placebo Lonafarnib) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Farnesyltransferase inhibitor. Area: Oncology.

phase 3 Farnesyltransferase inhibitor Farnesyltransferase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Lonafarnib (Placebo Lonafarnib) — Eiger BioPharmaceuticals. Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo Lonafarnib TARGET	Placebo Lonafarnib	Eiger BioPharmaceuticals	phase 3	Farnesyltransferase inhibitor	Farnesyltransferase
Zokinvy	LONAFARNIB	Sentynl Theraps Inc	marketed	Farnesyltransferase Inhibitor [EPC]	farnesyltransferase	2020-01-01
Tipifarnib;Zarnestra; R115777	Tipifarnib;Zarnestra; R115777	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Farnesyltransferase inhibitor	Farnesyltransferase
Gemcitabine with R115777	Gemcitabine with R115777	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Nucleoside analog + farnesyltransferase inhibitor combination	Ribonucleotide reductase (gemcitabine); farnesyltransferase (R115777)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Farnesyltransferase inhibitor class)

Eiger BioPharmaceuticals · 1 drug in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Lonafarnib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-lonafarnib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing